Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO® (selinexor) to the Pharmaceutical Administration...
Ubitus and Smart Surgery enable doctors to practice robotic surgery with VR streaming
TOKYO, Dec. 22, 2022 /PRNewswire/ -- Ubitus K.K. (hereinafter Ubitus), a world-leading metaverse solution provider, supports Smart Surgery Technology to roll out its VR driven surgery simulation application – Sim Surgery. Smart Surgery Technology successfully demonstrated this innovative product at Medical Taiwan Exhibition from the 1st to the 4th of December, 2022. ...
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
Exploring Xanamem® and the "cortisol hypothesis" for more than 6 million Americans suffering from Alzheimer's Disease SYDNEY, Dec. 22, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical trial of...
P3 Research secures investment from Genesis Capital to accelerate expansion
P3 is a leading New Zealand clinical trial site network founded in 1998 With sites in seven locations throughout New Zealand, P3's clients range from large multi-nationals to small biotechs globally Genesis Capital has become the major shareholder of the clinical trials group alongside existing shareholders WELLINGTON, New Zealand, Dec. 22, 2022 /PRNewswire/ -- P3 Research,...
U.S. FDA Approves Clinical Trial Application for IASO Bio’s BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 22, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products,, today announced that the Investigational New Drug (IND) application for its in-house developed BCMA CAR-T CT103A (equecabtagene autoleucel) has been...
New STIC trial data shows longer overall survival for therapy selection based on CELLSEARCH® CTC count in patients with metastatic breast cancer
Integration of CTC (Circulating Tumor Cell) enumeration* to decide between endocrine therapy and chemotherapy may lead to improved clinical outcomes and quality of life for patients with oestrogen receptor (ER) positive)/human epidermal growth factor receptor (HER) 2 negative metastatic breast cancer (MBC). BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 22, 2022 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of...
Gemini Rosemont adds Peninsula Life Science Center eight-story office building to portfolio in all cash transaction
LOS ANGELES, Dec. 22, 2022 /PRNewswire/ -- Gemini Rosemont Commercial Real Estate, a vertically integrated real estate investment management firm specializing in Class A multi-tenant office and luxury residential properties, has acquired Peninsula Life Science Center for $59,350,000. Gemini Rosemont adds Peninsula Life Science Center eight-story office building to West...
Everest Medicines’ Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
SHANGHAI, Dec. 22, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received acceptance from the U.S. Food and Drug Administration (FDA) for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC). The FDA's decision is expected in the second half of...
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) in February 2023 Telix pipeline featured across seven presentations including first reveal of the...
Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease
SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will be presenting at the Biotech Showcase during JPM week, taking place in San Francisco, CA, USA from January 9 to 11, 2023. Nuevocor will also be giving an oral presentation on new pre-clinical data for its LMNA cardiac gene therapy...
